Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

Add Yahoo as a preferred source to see more of our stories on Google. In a new trial, migraine drug ubrogepant (Ubrelvy) helped stop headaches in their tracks, allowing sufferers to go about their ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a ...

The Food and Drug Administration (FDA) has recently intervened regarding a migraine medication advertisement featuring tennis superstar Serena Williams. The FDA’s concerns center around claims that ...

On August 29, 2024, the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) issued an untitled letter to AbbVie, Inc. (AbbVie) regarding a promotional, ...

There’s fewer headaches around for companies that make and market migraine drugs, which are tracking substantial revenue growth. During Pfizer’s Q4 earnings call on Tuesday, chairman/ CEO Albert ...

An already approved drug can effectively prevent a coming migraine, trial results show Ubrogepant (Ubrelvy) warded off migraine within a couple of hours in 73% of patients The drug blocks a small ...

On a rainy, hot South Florida day, Sophia Gonzon’s head throbs. Hovered over her, Dr. Maike Blaya injects Botox into the young woman’s scalp, jaw, neck, forehead and shoulders. Gonzon closes her eyes, ...

Ubrelvy (ubrogepant) is a brand-name prescription drug used to treat migraine episodes. It is a type of drug called a calcitonin gene-related peptide (CGRP) antagonist. If a person has a Medicare Part ...

Medicare may cover Ubrelvy (ubrogepant) if you have a plan with prescription drug coverage, such as a Part D plan or a Medicare Advantage (Part C) plan. Ubrelvy is a brand-name drug that doctors may ...

The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a migraine medication commercial featuring Serena Williams is “misleading.